memo-vantage-point-markman-outcome.docx

1014-00003 · Optiwave Semiconductor Corp · Post-Markman Assessment

memo-vantage-point-markman-outcome.docx DOCUMENT Litigation

59 / 83 ← → ✕

MEMORANDUM

February 23, 2023

FROM: Alan Ngo, Responsible Partner, intellectual Property Group Calderwood & Harkness LLP One Embarcadero Center, 34th Floor San Francisco, CA 94111

TO: Douglas Fairbanks III, Managing Partner Vantage Point Capital Partners Fund IV, LP 2600 Sand Hill Road, Suite 200 Menlo Park, CA 94025

Rebecca Torres, Operating Partner (Semiconductor Sector) Vantage Point Capital Partners Fund IV, LP 2600 Sand Hill Road, Suite 200 Menlo Park, CA 94025

RE: Post-Markman Litigation Value Assessment — Optiwave Semiconductor Corp. v. Lumos Photonics, Inc., Case No. 5:22-cv-03417-EJD (N.D. Cal.)

C&H MATTER NO.: 1014-00003

COPIES: Sandra Ellison, General Counsel, Optiwave Semiconductor Corp. (privileged copy) Marcus Delgado, Billing Partner, Calderwood & Harkness LLP (privileged copy) Omar Siddiqui, Lead Associate, Calderwood & Harkness LLP (privileged copy)

Right-click to update Table of Contents

I. Executive Summary

The purpose of this memorandum is to advise Vantage Point Capital Partners Fund IV, LP ("Vantage Point" or "VPCP"), as the majority shareholder holding approximately 62% of the outstanding equity of Optiwave Semiconductor Corp. ("OWS" or the "Company"), regarding the material adverse impact of the Markman claim construction order (the "Markman Order") issued on February 17, 2023, by the Honorable Edward J. Torvelis of the United States District Court for the Northern District of California, on the value of OWS's patent infringement litigation against Lumos Photonics, Inc. ("Lumos" or "Defendant"). This memorandum is being provided in advance of the OWS Board of Directors meeting scheduled for February 24, 2023, at which the Board will consider next steps, including settlement authorization.

The Markman Order construed all eleven disputed claim terms across the four patents-in-suit: U.S. Patent Nos. 10,234,567 (the "'567 Patent"), 10,891,234 (the "'234 Patent"), 11,045,678 (the "'678 Patent"), and 11,312,890 (the "'890 Patent"). The outcome was overwhelmingly unfavorable to OWS. The Court adopted Defendant's proposed constructions, or constructions substantially aligned with Defendant's proposals, on eight of the eleven disputed claim terms. The Court adopted Plaintiff's proposed constructions on only two terms and issued a modified construction on one additional term that, in substance, remains closer to Defendant's position than to Plaintiff's.

The bottom-line assessment of Calderwood & Harkness's intellectual Property Group is as follows: the Court's narrow constructions render OWS's infringement theories untenable as to three of the four asserted patents (the '567 Patent, the '234 Patent, and the '678 Patent) and significantly weakened as to the fourth (the '890 Patent). The accused Lumos products — the LumosBridge™ 800G Optical Engine and the LumosEdge™ 400ZR+ Pluggable Transceiver — fall outside the scope of the asserted claims as now construed by the Court, with the possible narrow exception of certain claims of the '890 Patent, where only a slim and high-risk doctrine-of-equivalents theory survives, undermined by prosecution history estoppel.

The pre-litigation collective valuation of the four asserted patents at $42.8 million, as determined by Clearpath IP Valuation Services, Inc. in its independent appraisal, is materially impaired. That valuation assumed a reasonable probability of obtaining favorable claim constructions and sustaining infringement theories — an assumption that the Markman Order has now invalidated. The expected litigation recovery, previously estimated at in excess of $75 million based on a reasonable royalty damages theory, has been reduced to near-zero.

Calderwood & Harkness recommends that OWS pursue settlement discussions with Lumos through its litigation counsel, Brannick Howell & Stein LLP. A Board meeting is scheduled for February 24, 2023, to discuss settlement authority and next steps. This memorandum is intended to provide Vantage Point with a comprehensive assessment so that its Board representatives can participate in that discussion on a fully informed basis.

We note that Vantage Point's $74.5 million equity investment in OWS (through the Series C and Series D rounds) is not directly at risk from this development. However, OWS's IP portfolio value — which is a significant driver of the Company's enterprise value and a material factor in any future exit transaction, whether by way of M&A or IPO — is diminished by the Markman Order. The implications for Vantage Point's investment are discussed in detail below.

II. Background

A. The Litigation

Optiwave Semiconductor Corp. filed this patent infringement action on June 3, 2022, in the United States District Court for the Northern District of California, San Jose Division, asserting four U.S. patents against Lumos Photonics, Inc. The case was assigned to the Honorable Edward J. Torvelis and is docketed as Case No. 5:22-cv-03417-EJD.

Lumos Photonics, Inc. is a publicly traded company (Nasdaq: LMPH) headquartered in San Diego, California, that designs and manufactures photonic integrated circuits and optical transceiver modules for data center and telecommunications applications. As of the filing date of this action, Lumos's market capitalization was approximately $1.87 billion. Its largest institutional shareholder is Ridgeline Asset Management, LLC, which held an approximately 9.2% equity stake as of Lumos's most recent proxy filing. Lumos is represented in this litigation by Brannick Howell & Stein LLP, with Victoria Ashworth serving as lead partner.

The accused products are the LumosBridge™ 800G Optical Engine, a co-packaged optics module designed for next-generation data center switch architectures, and the LumosEdge™ 400ZR+ Pluggable Transceiver, a coherent optical transceiver conforming to the OIF 400ZR+ multi-source agreement specification. These are Lumos's two highest-revenue products and are central to the company's growth strategy in the data center interconnect market.

Combined accused product revenue for the LumosBridge™ and LumosEdge™ platforms was approximately $148.6 million for calendar year 2022, as determined from Lumos's annual report on Form 10-K filed with the Securities and Exchange Commission and corroborated by Lumos's discovery responses (specifically, Defendant's Supplemental Responses to Plaintiff's First Set of Interrogatories, served November 14, 2022). The pre-suit damages period, encompassing the first and second quarters of 2022 prior to the filing of the complaint, accounts for approximately $62.3 million of that revenue.

OWS's damages theory, as developed by Dr. Lawrence Kessler of Apex Claim Analytics LLC, is based on a reasonable royalty framework. The estimated royalty rate of 7.5%, derived from an analysis of comparable license agreements in the silicon photonics and optical transceiver industry, was applied to accused product revenue. With the addition of a willfulness enhancement based on OWS's pre-suit notice letters to Lumos (sent January 15, 2022, and March 28, 2022), the total claimed damages exceeded $75 million. This damages theory was developed in conjunction with C&H's litigation team and was the basis for the Board's decision to authorize litigation in April 2022.

The OWS Board of Directors approved a litigation budget of $4.2 million to fund the case through trial, which was projected for the fourth quarter of 2023 under Judge Torvelis's scheduling order. As of the date of this memorandum, total litigation expenditures amount to approximately $2,549,568, comprised of the following:

The remaining estimated cost to litigate through trial is approximately $1.65 million, which would bring total expenditures to approximately $4.2 million — essentially the full approved budget. These estimates are detailed in the litigation financial summary attached as Appendix E.

B. Pre-Litigation Patent Valuation

Prior to filing suit, and in connection with the Board's evaluation of whether to authorize the litigation, OWS engaged Clearpath IP Valuation Services, Inc. to conduct an independent valuation of OWS's U.S. patent portfolio. The engagement was led by Jennifer Armitage, CFA, CLP, Clearpath's Managing Director and lead analyst for semiconductor and photonics IP valuations.

Clearpath valued OWS's total patent portfolio — consisting of 87 issued U.S. patents at the time of the valuation — at $215 million. An additional 14 pending U.S. patent applications were identified but not separately valued, consistent with Clearpath's methodology of valuing only issued patents. The valuation was conducted using an income-based approach that incorporated comparable license rates from arms-length transactions in the silicon photonics, optical transceiver, and semiconductor industries, as well as projected royalty streams from potential licensees based on market sizing and technology adoption forecasts.

The four patents subsequently asserted in this litigation were collectively valued at $42.8 million, representing approximately 19.9% of the total portfolio value. This disproportionate concentration of value in four patents reflected Clearpath's assessment that the asserted patents covered commercially significant and widely practiced technology in the silicon photonics market, including adiabatic waveguide coupling, germanium-on-silicon photodetector architectures, monolithic wavelength-division multiplexing integration, and co-integrated modulator driver circuits.

Critically, Clearpath's valuation assumed a reasonable probability of obtaining favorable claim constructions in litigation and sustaining infringement theories against accused products employing the covered technologies. This assumption was expressly stated in the valuation report and was a material input to the income-based valuation model. As discussed in detail below, this assumption has been invalidated by the Markman Order. The full Clearpath valuation report summary is attached as Appendix D.

C. Vantage Point's Investment Position

Vantage Point Capital Partners Fund IV, LP, a venture capital fund with a 2018 vintage and $2.1 billion in committed capital, is the majority equity holder in OWS. VPCP invested a total of $74.5 million in OWS through two rounds of equity financing: the Series C round (closed August 2019) and the Series D round (closed February 2021). As a result of these investments, VPCP holds approximately 62% of OWS's outstanding equity on a fully diluted basis and controls three of the seven seats on the OWS Board of Directors.

OWS is a fabless semiconductor company specializing in silicon photonics-based coherent optical transceiver chipsets and co-packaged optics engines for data center interconnect applications. The Company's flagship products include the OWS-400ZR coherent optical transceiver chipset, the OWS-800LR long-reach coherent optical engine, and related silicon photonics engines manufactured by Pinnacle Semiconductor Foundry Co., Ltd. on a 45nm silicon-on-insulator (SOI) process. OWS reported fiscal year 2022 revenue of $187.4 million, reflecting strong growth driven by hyperscale data center demand for high-bandwidth optical interconnects.

OWS's intellectual property portfolio is a core component of the Company's enterprise value. The portfolio serves both defensive purposes — providing freedom to operate and cross-licensing leverage against competitors — and offensive purposes, supporting potential licensing revenue and patent assertion against infringers. The IP portfolio has been identified as a key asset in Vantage Point's exit planning, whether through a strategic acquisition by a larger semiconductor or photonics company or through an initial public offering. The Markman Order's impact on the portfolio value is therefore directly relevant to Vantage Point's investment thesis and return expectations.

III. Summary of the Markman Order (February 17, 2023)

On February 17, 2023, the Court issued a 34-page order construing all eleven disputed claim terms across the four patents-in-suit. The full text of the Markman Order is attached as Appendix A. A side-by-side comparison chart showing OWS's proposed constructions, Lumos's proposed constructions, and the Court's adopted constructions for each of the eleven terms is attached as Appendix B.

The Markman hearing was held on January 30, 2023, and lasted approximately six and a half hours. The hearing included live testimony from two technical tutorial witnesses. Dr. Harold Whitfield of Whitfield Technical Consulting Group testified on behalf of OWS, providing a tutorial on silicon photonics device architecture, adiabatic coupling structures, germanium photodetector fabrication, and modulator driver integration. Dr. Raymond Ng, serving as a technical consultant of counsel to Brannick Howell & Stein LLP, testified on behalf of Lumos, presenting a competing tutorial focused on distinguishing monolithic integration from heterogeneous integration techniques, continuous versus step-graded semiconductor buffer layers, and the state of the art in multi-chip packaging for optical transceivers.

The overall scorecard of the Markman Order is as follows:

This is an unusually lopsided result. In C&H's experience litigating patent cases before Judge Torvelis, outcomes in this range — with the defendant prevailing on more than 70% of disputed terms — occur in fewer than 15% of Markman proceedings. The result reflects, in our assessment, a combination of factors: (i) the prosecution histories of the asserted patents, which included multiple amendments and applicant remarks narrowing claim scope to overcome prior art, (ii) effective advocacy by Victoria Ashworth and the Brannick Howell & Stein team, whose intrinsic-evidence analysis was thorough and well-organized, and (iii) certain vulnerabilities in OWS's claim language that, while identified in C&H's pre-suit claim construction risk assessment, were assessed as presenting a moderate rather than high risk of adverse construction. We discuss each of the critical term constructions in turn below, focusing on the four terms with the most significant impact on OWS's infringement theories.

A. '567 Patent — "Adiabatically Coupled" (U.S. Patent No. 10,234,567)

The '567 Patent is directed to adiabatic waveguide coupling structures for silicon photonic integrated circuits. The key disputed term was "adiabatically coupled," which appears in independent Claim 1 and is incorporated by reference into dependent Claims 4, 7, 12, and 15 — the five claims asserted against Lumos.

The parties' competing constructions and the Court's adopted construction are as follows:

OWS's Proposed Construction: "coupled such that optical mode transitions occur without significant power loss."

Lumos's Proposed Construction: "coupled through a gradual, continuous taper that prevents excitation of higher-order modes throughout the entire transition region."

Court's Adopted Construction: "coupled through a gradual, continuous taper designed and configured to prevent excitation of higher-order modes over the entire transition length."

The Court adopted Defendant's proposed construction with only minor, non-substantive modification (replacing "throughout the entire transition region" with "over the entire transition length"). In substance, the Court's construction is identical to Lumos's proposal and imposes the critical limitation that adiabatic coupling, as used in the '567 Patent claims, requires a "gradual, continuous taper."

The critical impact of this construction on OWS's infringement theory is as follows. Lumos's LumosBridge™ 800G Optical Engine employs a segmented, non-continuous taper structure in its waveguide coupling architecture. The Lumos design uses discrete coupling sections — rather than a single continuous taper — to transition optical modes between waveguide layers. Under OWS's proposed construction, which focused on the functional result ("without significant power loss") rather than the structural means, the Lumos segmented taper design would have been captured. Under the Court's construction, which requires a "gradual, continuous taper," the Lumos segmented taper falls squarely outside the claim scope.

The Court's analysis relied heavily on the prosecution history of the '567 Patent. During prosecution, the claims were narrowed by amendment to add the limitation "adiabatically coupled" to overcome a prior art rejection based on U.S. Patent No. 9,456,012, issued September 6, 2016, to Hideo Tanaka (the "Tanaka Patent"). In an irony not lost on either party, Dr. Tanaka is a co-inventor of the Tanaka Patent who subsequently left his prior employer and joined OWS, where he serves as a principal design engineer and contributed to the development of the technology covered by the '567 Patent. The applicant's remarks submitted during prosecution in connection with the amendment adding "adiabatically coupled" distinguished the claimed invention from the Tanaka Patent by emphasizing the gradual, continuous nature of the taper structure. The Court found this prosecution history disclaimer significant, stating that "the applicant's own characterization of 'adiabatic coupling' as requiring a 'gradual, continuous taper' to distinguish the Tanaka reference is entitled to substantial weight and limits the permissible construction of this term." Markman Order at 12.

As a result of this construction, all five asserted claims of the '567 Patent (Claims 1, 4, 7, 12, and 15) cannot be infringed by the accused Lumos products. Infringement is untenable, and no viable theory — whether literal or under the doctrine of equivalents — survives given the prosecution history estoppel arising from the narrowing amendment.

B. '234 Patent — "Continuously Varying Germanium Concentration" (U.S. Patent No. 10,891,234)

The '234 Patent is directed to germanium-on-silicon photodetector structures for use in silicon photonic receivers. The key disputed term was "graded buffer layer having a continuously varying germanium concentration," which appears in independent Claim 1 and is incorporated into dependent Claims 3, 5, 8, and 11 — the five claims asserted against Lumos.

The parties' competing constructions and the Court's adopted construction are as follows:

OWS's Proposed Construction: "a buffer layer in which the germanium concentration changes across the layer thickness."

Lumos's Proposed Construction: "a buffer layer in which the germanium atomic fraction increases monotonically and without step changes from the silicon substrate interface to the absorber layer."

Court's Adopted Construction: The Court adopted Defendant's proposed construction verbatim: "a buffer layer in which the germanium atomic fraction increases monotonically and without step changes from the silicon substrate interface to the absorber layer."

The critical impact of this construction on OWS's infringement theory is as follows. Lumos's photodetector design, as used in both the LumosBridge™ and LumosEdge™ platforms, employs a step-graded silicon-germanium (SiGe) buffer layer with four discrete composition steps. The germanium atomic fractions at each step are 0.25, 0.50, 0.75, and 1.0, progressing from the silicon substrate interface to the germanium absorber layer. This step-graded structure — in which the germanium concentration increases in discrete increments rather than varying continuously — is clearly excluded by the Court's construction requiring a monotonic increase "without step changes."

The Court acknowledged that the '234 Patent specification describes both "continuously graded" and "step-graded" buffer layer embodiments. Indeed, the specification at column 5, lines 22-38, includes a figure and textual description of a step-graded buffer layer as an alternative embodiment. OWS argued that this disclosure supported a broader construction that would encompass both continuous and step-graded structures. The Court disagreed, finding that while the specification described both embodiments, the claim language uses only the term "continuously varying," which the Court held "unambiguously excludes step-graded structures in which the germanium concentration changes in discrete, discontinuous increments." Markman Order at 18. The Court noted that the patentee could have drafted the claims to cover both embodiments — for example, by using the term "graded" without the "continuously varying" modifier — but chose not to do so. The claim language controls and limits the scope to continuous gradation.

As a result of this construction, all five asserted claims of the '234 Patent (Claims 1, 3, 5, 8, and 11) are foreclosed. The Lumos step-graded buffer layer falls outside the claim scope, and no viable infringement theory survives.

C. '678 Patent — "Monolithically Formed" (U.S. Patent No. 11,045,678)

The '678 Patent is directed to integrated wavelength-division multiplexing (WDM) elements for silicon photonic transmitter circuits. The key disputed term was "integrated wavelength-division multiplexing element monolithically formed on a single silicon die," which appears in independent Claim 1 and is incorporated into dependent Claims 2, 6, 9, and 14 — the five claims asserted against Lumos.

The parties' competing constructions and the Court's adopted construction are as follows:

OWS's Proposed Construction: "a WDM component fabricated as part of the same semiconductor fabrication process on a single die."

Lumos's Proposed Construction: "a WDM component formed during front-end-of-line processing within the same silicon substrate, excluding hybrid integration, flip-chip bonding, or any heterogeneous integration technique."

Court's Adopted Construction: "fabricated entirely within the same front-end-of-line and back-end-of-line semiconductor processing sequence on a single silicon substrate without heterogeneous bonding or attachment of separately fabricated optical components."

The Court largely adopted Defendant's proposed construction, though it expanded the scope slightly to include back-end-of-line processing (which Lumos's proposal had arguably excluded) while retaining the critical exclusion of heterogeneous integration techniques. The net result is a construction that requires fully monolithic fabrication — the WDM element must be fabricated entirely within the same semiconductor processing sequence on a single silicon substrate, without the bonding or attachment of separately fabricated components.

The critical impact on OWS's infringement theory is severe. Lumos's 800G optical engine platform utilizes micro-transfer-printed III-V gain elements (indium phosphide-based semiconductor optical amplifiers) that are bonded onto the silicon photonic integrated circuit (PIC) die. This micro-transfer printing process is a form of heterogeneous integration in which separately fabricated III-V semiconductor components are picked and placed onto the silicon die — a technique that falls squarely outside the Court's construction requiring monolithic fabrication "without heterogeneous bonding or attachment of separately fabricated optical components."

The prosecution history of the '678 Patent was particularly damaging. The term "monolithically formed" was added by amendment during prosecution to overcome a prior art rejection based on references describing hybrid integration approaches. In the applicant's remarks accompanying the amendment, OWS's prosecution counsel stated: "The present invention is distinguished from heterogeneous integration approaches in that the WDM element is monolithically formed — i.e., fabricated entirely within the same processing sequence on a single silicon substrate, without the need for bonding or attaching separately fabricated optical components." The Court relied heavily on this prosecution history disclaimer, characterizing it as "an unambiguous disavowal of heterogeneous integration that confines the claim scope to monolithic fabrication." Markman Order at 24.

As a result, all five asserted claims of the '678 Patent (Claims 1, 2, 6, 9, and 14) are foreclosed. The Lumos micro-transfer-printed III-V gain elements are excluded by the "monolithically formed" construction.

D. '890 Patent — "Co-Integrated" (U.S. Patent No. 11,312,890)

The '890 Patent is directed to pre-emphasis equalization driver circuits for silicon photonic modulators. The key disputed term was "pre-emphasis equalization stage electrically co-integrated with the modulator on a common substrate," which appears in independent Claim 1 and is incorporated into dependent Claims 5, 8, and 13 — the four claims asserted against Lumos.

The parties' competing constructions and the Court's adopted construction are as follows:

OWS's Proposed Construction: "an equalization circuit located on the same substrate as the modulator."

Lumos's Proposed Construction: "an equalization circuit fabricated in the same semiconductor process as the modulator, sharing the same doping profiles and process layers, and electrically connected without bond wires, interposers, or package-level routing."

Court's Adopted Construction: The Court adopted Defendant's proposed construction in full: "an equalization circuit fabricated in the same semiconductor process as the modulator, sharing the same doping profiles and process layers, and electrically connected without bond wires, interposers, or package-level routing."

The impact of this construction on OWS's infringement theory is significant. Lumos's modulator driver architecture uses a separate CMOS driver die that is flip-chip bonded to the silicon photonic modulator die via copper pillar micro-bumps. The driver die and the modulator die are fabricated in different semiconductor processes (the driver in a 16nm FinFET CMOS process, the modulator in a 45nm SOI silicon photonics process), and they are electrically connected through the copper pillar micro-bumps — which constitute "bond" connections excluded by the Court's construction. The Lumos architecture is therefore outside the literal scope of the claims as construed.

Unlike the other three patents, however, the '890 Patent presents a theoretically possible — though weak — doctrine-of-equivalents argument. One could argue that Lumos's flip-chip bonded driver performs substantially the same function (pre-emphasis equalization), in substantially the same way (electrical signal conditioning applied to the modulator), to achieve substantially the same result (improved modulator performance) as a co-integrated driver. However, this argument is significantly undermined by prosecution history estoppel. The term "co-integrated" was added during prosecution specifically to distinguish the claimed invention from prior art describing separately fabricated and bonded driver circuits. The prosecution history therefore creates a strong estoppel argument that precludes extending the claims under the doctrine of equivalents to encompass the very bonded-driver configuration that the amendment was designed to exclude.

Additionally, the '890 Patent faces a non-trivial invalidity risk. During claim construction briefing, Lumos identified a prior art publication — Iyer & Patel, "Co-Design of Modulator Drivers and Silicon Photonic Mach-Zehnder Structures," IEEE Transactions on Circuits and Systems, Vol. 65, No. 8, pp. 2701–2713 (2018) — that describes co-integrated driver circuits with pre-emphasis equalization on a common silicon substrate with a Mach-Zehnder modulator. While this reference was cited during prosecution and distinguished on other grounds, it remains relevant to Lumos's anticipated Section 103 obviousness defense, particularly if the claims are construed broadly enough to reach Lumos's flip-chip bonded architecture.

In sum, the asserted claims of the '890 Patent (Claims 1, 5, 8, and 13) are significantly weakened though not entirely foreclosed. A slim doctrine-of-equivalents theory survives, but it is high-risk and would face both prosecution history estoppel and potential invalidity challenges at summary judgment and trial.

IV. Impact on Litigation Value

A. Infringement Viability Assessment

Based on the Markman Order, Calderwood & Harkness has conducted a comprehensive reassessment of the viability of OWS's infringement theories against each of the four asserted patents. The detailed claim-by-claim infringement viability analyses are attached as Appendix C. The summary assessment for each patent is as follows:

'567 Patent (U.S. Patent No. 10,234,567) — Infringement Untenable. The Court's construction of "adiabatically coupled" as requiring a "gradual, continuous taper" excludes the Lumos LumosBridge™ segmented (non-continuous) taper design. All five asserted claims (Claims 1, 4, 7, 12, and 15) depend on this term. Prosecution history estoppel arising from the narrowing amendment to overcome the Tanaka prior art precludes any viable doctrine-of-equivalents theory. This patent is effectively out of the case.

'234 Patent (U.S. Patent No. 10,891,234) — Infringement Untenable. The Court's construction of "continuously varying germanium concentration" as requiring a monotonic increase "without step changes" excludes the Lumos step-graded SiGe buffer layer with four discrete composition steps (Ge fractions of 0.25, 0.50, 0.75, and 1.0). All five asserted claims (Claims 1, 3, 5, 8, and 11) are foreclosed. No viable alternative infringement theory exists.

'678 Patent (U.S. Patent No. 11,045,678) — Infringement Untenable. The Court's construction of "monolithically formed" as excluding "heterogeneous bonding or attachment of separately fabricated optical components" excludes the Lumos micro-transfer-printed III-V gain elements bonded to the silicon PIC. All five asserted claims (Claims 1, 2, 6, 9, and 14) are foreclosed. The prosecution history disclaimer — in which the applicant expressly distinguished the invention from heterogeneous integration approaches — eliminates any doctrine-of-equivalents theory.

'890 Patent (U.S. Patent No. 11,312,890) — Infringement Significantly Weakened. The Court's construction of "co-integrated" as requiring fabrication "in the same semiconductor process" and connection "without bond wires, interposers, or package-level routing" excludes the Lumos flip-chip bonded CMOS driver die. The four asserted claims (Claims 1, 5, 8, and 13) survive only under a slim doctrine-of-equivalents theory, which is substantially undermined by prosecution history estoppel and faces additional invalidity risk from the Iyer & Patel prior art reference.

Net Assessment: Three of the four asserted patents are effectively out of the case. The fourth patent offers only a marginal, high-risk infringement theory with a low probability of surviving summary judgment. The litigation posture has shifted from one in which OWS held a credible multi-patent infringement case to one in which OWS's claims are, for practical purposes, non-viable.

B. Damages Implications

The adverse claim constructions have a cascading effect on OWS's damages case. The previously estimated damages of in excess of $75 million were predicated on a reasonable royalty theory applying a 7.5% royalty rate to the full $148.6 million in combined accused product revenue for the LumosBridge™ and LumosEdge™ platforms, with an additional willfulness enhancement. This damages framework assumed that all four asserted patents would be in play and that the accused products, in their entirety, practiced the claimed inventions.

With only the '890 Patent potentially remaining in the case — and weakly — the damages analysis must be fundamentally reconsidered. The '890 Patent relates specifically to the pre-emphasis equalization driver circuit architecture. Under accepted apportionment principles, the royalty base for a single component-level patent covering only the driver circuit would need to be limited to the portion of accused product revenue attributable to the driver circuit architecture, rather than the full product revenue. The driver circuit represents a small fraction of the overall value of the LumosBridge™ and LumosEdge™ platforms, which derive their commercial value primarily from the complete photonic integrated circuit — including the waveguide coupling, photodetector, WDM multiplexer, and modulator elements (the very components addressed by the three foreclosed patents).

Dr. Lawrence Kessler's preliminary damages framework, developed on behalf of OWS by Apex Claim Analytics LLC, is effectively mooted by the Markman Order. The framework was designed as a multi-patent damages model apportioning royalty value across all four asserted patents. With three patents eliminated, the model cannot simply be scaled down — it must be rebuilt from the ground up, an exercise that would require additional expert fees and would yield a dramatically reduced damages figure.

Even under the most optimistic assumptions — if the '890 Patent infringement theory survived summary judgment and the case proceeded to trial on that single patent — the expected recovery would be in the low single-digit millions at most. A royalty rate of 2-3% (reflecting the narrower technology contribution of the driver circuit alone) applied to a reduced royalty base (the driver-attributable portion of accused product revenue, estimated at 8-12% of total product revenue, or approximately $12-18 million) would yield a pre-enhancement royalty of approximately $240,000 to $540,000. Even with a willfulness enhancement (which would be difficult to sustain given the post-Markman posture), the total recovery would be unlikely to exceed $1.5-2.0 million — well below the remaining litigation cost to reach trial.

C. Revised Expected Value Calculation

The litigation expected value calculation has changed dramatically as a result of the Markman Order. The following table summarizes the pre-Markman and post-Markman expected value assessments:

The pre-Markman expected value of the litigation was estimated at $35–50 million on a probability-weighted basis. This estimate incorporated a 45-65% probability of a favorable overall outcome (accounting for claim construction risk, summary judgment risk, and trial risk), multiplied by expected damages in the $55-80 million range (reflecting the full multi-patent damages theory with some discount for litigation uncertainty). This expected value supported the Board's decision to authorize the filing of the lawsuit and the allocation of a $4.2 million litigation budget.

The post-Markman expected value is estimated at less than $2 million. This reflects a probability of less than 5% that OWS will achieve a favorable outcome on the '890 Patent alone (accounting for the slim doctrine-of-equivalents theory, prosecution history estoppel, invalidity risk, and summary judgment risk), multiplied by a reduced damages figure of $1.5-2.0 million. Against the remaining estimated litigation cost of approximately $1.65 million to reach trial, the net expected value of continued litigation is negative.

In plain terms, OWS would be expected to spend more on continued litigation than it would expect to recover, on a probability-weighted basis. The rational economic decision is to discontinue affirmative pursuit of the case and seek to resolve the matter through settlement.

V. Impact on Patent Portfolio Valuation

A. The Four Asserted Patents

The most immediate valuation impact of the Markman Order falls on the four asserted patents. Clearpath IP Valuation Services' pre-litigation valuation of these four patents at a collective $42.8 million must be materially revised downward.

The Court's narrow constructions do not merely impair OWS's ability to assert these patents against Lumos — they reduce the effective scope of each patent for all purposes, including licensing to third parties, assertion against other potential infringers, and use as defensive assets in cross-licensing negotiations. The key claim terms that were narrowly construed — "adiabatically coupled," "continuously varying germanium concentration," "monolithically formed," and "co-integrated" — are the same terms that define the breadth of each patent's coverage in the marketplace. A patent that covers only continuous tapers and not segmented tapers, only continuous grading and not step grading, only monolithic fabrication and not heterogeneous integration, and only same-process co-integration and not multi-chip bonded architectures, is a patent that covers a much smaller universe of potentially infringing products than previously assumed.

While the Markman Order is technically binding only in this case and not in other jurisdictions, any future assertion of these four patents — whether in a new infringement action in another district court, in an International Trade Commission investigation, or in a licensing negotiation — will be significantly influenced by the existing constructions. Accused infringers and potential licensees will point to the Markman Order as persuasive authority for a narrow reading of the claims. Although a different court could, in theory, adopt a different construction, the practical reality is that the existing constructions will anchor any future claim construction analysis and make it extremely difficult for OWS to obtain the broader constructions it originally sought.

The estimated revised value of the four asserted patents is significantly impaired, potentially to $5-10 million or less. The precise value will depend on whether any third-party products or technologies fall within the narrow constructions adopted by the Court, and on the remaining commercial life of the patents (the earliest expiration date among the four patents is 2037). C&H recommends that Clearpath be engaged to conduct a formal revaluation of these four patents in light of the Markman Order.

B. Broader Portfolio Implications

The impact of the Markman Order extends beyond the four asserted patents to OWS's broader patent portfolio. OWS holds 87 issued U.S. patents and 14 pending U.S. patent applications. The portfolio is concentrated in three primary technology areas: (i) waveguide coupling structures (including adiabatic and evanescent coupling), (ii) germanium-on-silicon photodetector architectures (including buffer layer designs and epitaxial growth techniques), and (iii) modulator driver and transceiver integration architectures (including co-packaged optics designs). These are the same technology areas directly impacted by the Markman Order.

While the Markman Order's claim constructions technically apply only to the four asserted patents, they establish judicial interpretive precedent for related claim language that appears throughout OWS's portfolio. Many of OWS's unasserted patents use similar or identical terminology — including "adiabatic," "continuously graded," "monolithic," and "co-integrated" — in their claims. A potential licensee or adverse party reviewing the portfolio in light of the Markman Order would reasonably conclude that these terms, if litigated, would receive similarly narrow constructions, thereby reducing the effective scope of the broader portfolio.

Based on a preliminary review of the claim language in OWS's portfolio, C&H estimates that the Markman Order may require a downward adjustment to Clearpath's portfolio-level valuation of $215 million in the range of 10-20%, or approximately $21.5-43.0 million. The precise magnitude of the adjustment will depend on a patent-by-patent analysis of how many additional patents share similarly vulnerable claim language and how dependent their value is on the breadth of the construed terms. C&H recommends that Clearpath IP Valuation Services be re-engaged to conduct an updated portfolio valuation incorporating the Markman Order and its implications for related patents.

Additionally, we note that OWS's IP portfolio serves as partial collateral for the Company's $40 million revolving credit facility with First Pacific Commerce Bank, N.A. ("FPCB"). The credit agreement includes customary representations regarding the value of collateral and may contain financial covenants tied to intangible asset values. Any material write-down of IP portfolio value could trigger covenant compliance discussions with FPCB. Sandra Ellison and C&H will coordinate on reviewing the specific covenant provisions and determining the appropriate disclosure to FPCB, as discussed further in Section VII.C below.

C. IP Monetization Strategy

The Markman Order has broader implications for OWS's IP monetization strategy. The Company's ability to use its patent portfolio as a licensing revenue stream — whether through affirmative licensing programs, patent assertion against infringers, or defensive cross-licensing arrangements with competitors — is diminished by the narrow claim constructions.

The constructions are particularly damaging because they narrow the patents' coverage in precisely the areas where the industry is trending. The silicon photonics industry has increasingly moved toward heterogeneous integration (using micro-transfer printing, wafer bonding, and other techniques to integrate III-V materials onto silicon photonic circuits), step-graded buffer layers (which are simpler to fabricate and more widely used than continuously graded buffers), segmented taper designs (which offer design flexibility advantages over continuous tapers), and multi-chip packaging with flip-chip bonding (which enables the use of advanced CMOS nodes for driver circuits while maintaining silicon photonics for the optical layer). The Markman Order's narrow constructions effectively exclude these industry-standard approaches from the scope of OWS's key patents, limiting the patents to a shrinking segment of the market that uses fully monolithic, continuously graded, and continuously tapered designs.

In the context of cross-licensing negotiations with competitors, OWS's leverage is reduced. The Company previously maintained a strong bargaining position based in part on the breadth of its patent portfolio and the credible threat of infringement assertions. The Markman Order weakens that threat and reduces the value that OWS can extract in cross-licensing arrangements.

Looking forward, OWS's patent prosecution strategy should be revisited. Pending patent applications should be drafted — or amended, if still possible within prosecution timelines — with claim language that avoids the vulnerabilities exposed in this Markman proceeding. In particular, claims should be drafted to explicitly cover both continuous and step-graded structures, both monolithic and heterogeneous integration, and both co-integrated and multi-chip bonded driver architectures, to the extent supported by the specification disclosures. Ted Marchetti, OWS's VP of IP, and OWS's patent prosecution counsel should be engaged to conduct this review promptly.

VI. Impact on OWS Enterprise Value and Exit Considerations

For purposes of Vantage Point's investment thesis and exit planning, the Markman Order's impact must be assessed in the context of OWS's overall enterprise value.

OWS's enterprise value is driven by several factors, including: (i) the Company's revenue-generating product business (the OWS-400ZR and OWS-800LR chipsets and silicon photonics engines), (ii) the Company's technology and engineering team, (iii) the Company's customer relationships with hyperscale data center operators and network equipment manufacturers, and (iv) the Company's intellectual property portfolio. The IP portfolio has historically been a significant component of enterprise value, serving both as a defensive moat protecting OWS's market position and as an independent source of potential licensing revenue.

The Markman Order's narrowing of key patent claims reduces both the defensive and offensive value of the IP portfolio. Defensively, the narrow constructions reduce OWS's ability to prevent competitors from entering the market with products that practice the broad technology concepts underlying OWS's patents — competitors can now employ segmented tapers, step-graded buffers, heterogeneous integration, and multi-chip bonded drivers without concern about infringing the asserted patents (and likely without concern about infringing other OWS patents that use similar claim language). Offensively, the narrow constructions reduce the licensing and assertion value of the portfolio, as discussed in Section V above.

In an M&A context, a potential acquirer's intellectual property due diligence would uncover the Markman Order. Any sophisticated acquirer — particularly a strategic acquirer in the semiconductor or photonics space — would review the claim constructions, assess their impact on the breadth and enforceability of the portfolio, and discount the IP component of the acquisition price accordingly. The magnitude of this discount would depend on the acquirer's specific interest in the patents (a company interested in the patents primarily for defensive purposes might apply a smaller discount than one interested in licensing revenue potential), but the Markman Order would unquestionably be a negative factor in acquisition negotiations.

In an IPO context, the diminished patent portfolio value would need to be disclosed in the Company's risk factors. A registration statement that failed to disclose the Markman Order and its impact on the portfolio would expose OWS and its officers and directors to securities liability. The disclosure itself — that a federal court narrowly construed key patent claims, rendering infringement theories untenable as to three of four asserted patents — would be a negative signal to public market investors evaluating OWS's competitive position and growth prospects.

It is important to note, however, that the Markman Order does not affect OWS's core revenue-generating business. OWS's product roadmap, customer relationships, manufacturing arrangements with Pinnacle Semiconductor Foundry, and market position in the coherent optical transceiver and co-packaged optics market remain intact. The Company reported strong fiscal year 2022 revenue of $187.4 million, and the demand for OWS's products from hyperscale data center customers continues to grow. The Markman Order affects only OWS's IP assertion capabilities — not its ability to design, manufacture, and sell its products. The Company's freedom to operate is not at issue, and OWS faces no counterclaim or declaratory judgment risk from Lumos that would threaten its product lines.

Accordingly, while the Markman Order represents a material impairment to one component of OWS's enterprise value, it does not fundamentally alter the Company's core business proposition. Vantage Point's investment thesis, to the extent it was predicated on OWS's product revenue growth and market position (rather than on IP monetization or litigation recovery), remains substantially intact.

VII. Recommended Course of Action

A. Settlement

Calderwood & Harkness recommends that OWS initiate settlement discussions with Lumos Photonics, Inc. through Lumos's litigation counsel, Brannick Howell & Stein LLP. The objective of these discussions should be to resolve the litigation on the most favorable terms available given OWS's significantly weakened post-Markman posture, while minimizing further expenditure of legal fees and management time.

Given the post-Markman posture, OWS's litigation leverage is minimal. Lumos is likely aware that its claim construction victories have effectively gutted OWS's case, and Victoria Ashworth and the BHS team will negotiate accordingly. Realistic settlement outcomes, in C&H's assessment, range from:

(a) A mutual cross-license agreement with nominal or de minimis royalty payments, providing both parties with freedom to operate under each other's patent portfolios going forward;

(b) A mutual walk-away with full mutual releases and covenant not to sue, with no monetary payment in either direction; or

(c) In a less favorable scenario, a settlement in which OWS agrees to dismiss the case with prejudice and pays a portion of Lumos's attorneys' fees in exchange for mutual releases (though C&H would resist this outcome).

Continuing the litigation through trial would cost an estimated additional $1.65 million — including expert deposition costs, summary judgment briefing, pretrial preparation, and trial itself — with a near-zero expected return. This expenditure would be economically irrational in light of the post-Markman expected value analysis set forth in Section IV.C above.

A Board meeting is scheduled for February 24, 2023, at which the Board will be asked to authorize settlement discussions and establish settlement parameters. This memorandum is intended to inform Vantage Point's position in advance of that discussion so that Vantage Point's three Board representatives can participate on a fully informed basis. C&H recommends that Vantage Point support settlement authorization and concur in a resolution that minimizes further expenditure while preserving OWS's relationship with the patent system and its ability to prosecute and enforce its broader portfolio going forward.

B. Portfolio Remediation

Independent of the settlement decision, C&H recommends the following portfolio remediation steps:

Updated Portfolio Valuation. Engage Clearpath IP Valuation Services, Inc. to conduct an updated valuation of OWS's full patent portfolio, reflecting the Markman Order and its implications for the four asserted patents as well as related patents in the portfolio that use similar claim language. This updated valuation will be necessary for financial reporting purposes, for assessing compliance with credit facility covenants, and for informing Vantage Point's enterprise value assessment and exit planning.

Pending Application Review. Work with Ted Marchetti (OWS VP of IP) and OWS's patent prosecution counsel to conduct a comprehensive review of all 14 pending U.S. patent applications. The objective of this review is to identify applications where claims can be amended — or continuation applications filed — with claim language drafted to cover broader embodiments of the claimed technology. Specifically, new or amended claims should be drafted to encompass:

(i) Segmented and discontinuous taper structures, in addition to continuous tapers;

(ii) Step-graded buffer layers, in addition to continuously graded buffers;

(iii) Heterogeneous integration techniques, including micro-transfer printing, wafer bonding, and flip-chip bonding, in addition to monolithic fabrication; and

(iv) Multi-chip bonded driver architectures, in addition to co-integrated same-process drivers.

This prosecution strategy, if executed promptly, could result in new patent claims that cover a broader range of industry-standard designs and partially offset the value impairment caused by the Markman Order. However, this is a medium-to-long-term effort, and new claims would need to be supported by adequate specification disclosure in the parent applications.

Reissue and Reexamination. C&H will evaluate whether any of the four asserted patents may be candidates for reissue under 35 U.S.C. § 251 or ex parte reexamination under 35 U.S.C. § 302, with the objective of obtaining broader claims that might survive the narrow constructions. Reissue is available within two years of patent issuance (or at any time to narrow claims), and the availability of reissue for the asserted patents will depend on whether the statutory requirements are met and whether broader claims can be obtained without running afoul of the prior art. This is a long-term effort with uncertain outcome, and C&H does not recommend relying on it as a primary remediation strategy.

C. Lender Communication

OWS's $40 million revolving credit facility with First Pacific Commerce Bank, N.A. includes OWS's IP portfolio as partial collateral. The Markman Order may constitute a material development that requires disclosure to FPCB under the credit agreement's reporting covenants. Sandra Ellison and C&H will coordinate on the following steps:

(a) Review the specific covenant provisions of the FPCB credit agreement to determine whether the Markman Order triggers any reporting obligations or covenant compliance issues;

(b) Assess whether the reduced IP portfolio value affects compliance with any financial covenants tied to intangible asset values or collateral coverage ratios; and

(c) Prepare appropriate disclosure communications to FPCB, in consultation with OWS's finance team and Vantage Point, that accurately describe the Markman outcome without unnecessarily alarming the lender or jeopardizing the credit relationship.

This communication should be handled carefully. The objective is to maintain transparency with the lender while avoiding any overstatement of the impact that could lead FPCB to declare a default, accelerate the facility, or impose onerous additional conditions.

D. Lessons for Future IP Strategy

The Markman outcome provides important lessons for OWS's future IP strategy, both in prosecution and in litigation:

Claim Construction Risk Assessment. Pre-suit claim construction risk assessment should incorporate more rigorous Markman simulation, including adversarial construction of key claim terms. C&H's pre-suit assessment identified the construed terms as presenting moderate risk, but a more rigorous analysis — including engagement of an outside claim construction expert to develop and argue adversarial constructions — might have more accurately assessed the risk as high and potentially altered the Board's decision to authorize litigation. Going forward, C&H recommends that any patent assertion decision be preceded by a formal adversarial claim construction exercise in which C&H attorneys role-play both sides and present competing constructions to a neutral evaluator.

Patent Prosecution Discipline. Patent prosecution should avoid amendments that create prosecution history estoppel narrowing claims beyond the intended scope. The Markman Order was heavily influenced by prosecution history disclaimers made during the prosecution of the '567 Patent (where "adiabatically coupled" was added to overcome the Tanaka prior art, with applicant remarks emphasizing continuous tapers) and the '678 Patent (where "monolithically formed" was added to overcome hybrid integration references, with applicant remarks expressly distinguishing heterogeneous integration). In both cases, the amendments and accompanying remarks were made to overcome specific prior art rejections, but they had the unintended consequence of narrowing the claims far more than may have been necessary. OWS's prosecution counsel should adopt a more disciplined approach to claim amendments, ensuring that narrowing language is no broader than necessary to overcome the specific prior art at issue and that applicant remarks are carefully drafted to avoid sweeping disclaimers.

VIII. Conclusion

The Markman Order issued on February 17, 2023, in Optiwave Semiconductor Corp. v. Lumos Photonics, Inc., Case No. 5:22-cv-03417-EJD, represents a materially adverse development for OWS. The Court's adoption of narrow, Defendant-aligned claim constructions on eight of eleven disputed terms substantially eliminates OWS's ability to prove infringement and recover damages from Lumos Photonics.

Three of the four asserted patents — the '567 Patent, the '234 Patent, and the '678 Patent — are effectively out of the case. The fourth, the '890 Patent, survives only under a slim doctrine-of-equivalents theory that is undermined by prosecution history estoppel and faces additional invalidity risk. The expected litigation recovery has been reduced from over $75 million to near-zero, and the net expected value of continued litigation is negative.

The total litigation spend to date of $2,549,568 — comprising $1,847,312 in C&H legal fees, $289,456 in litigation costs, and $412,800 in expert fees — will not be recovered. This is a sunk cost that must be accounted for in OWS's financial reporting.

The impairment extends beyond this lawsuit. The Markman Order diminishes the value of the four asserted patents for all purposes (licensing, assertion, cross-licensing), and the narrow constructions have broader implications for OWS's patent portfolio, which is concentrated in the same technology areas and uses similar claim language. The portfolio-level valuation may require a downward adjustment of 10-20%, with potential implications for the FPCB credit facility and for Vantage Point's exit planning.

Calderwood & Harkness recommends that Vantage Point support settlement authorization at the February 24, 2023 Board meeting and concur in a resolution that minimizes further expenditure. The litigation has reached a point where continued pursuit cannot be justified on economic grounds, and the Company's resources are better directed toward portfolio remediation and continued execution of its product business.

C&H remains available to discuss this memorandum with Vantage Point's deal team at any time prior to the Board meeting. Alan Ngo can be reached at the San Francisco office at (415) 555-0147 or by email at a.ngo@calderwoodharkness.com. We would welcome the opportunity to walk through the Markman Order and its implications in a call or in-person meeting at Vantage Point's convenience.

Respectfully submitted,

CALDERWOOD & HARKNESS LLP

By: ________

Alan Ngo Responsible Partner, intellectual Property Group One Embarcadero Center, 34th Floor San Francisco, CA 94111 (415) 555-0147 a.ngo@calderwoodharkness.com

Appendices

The following appendices are referenced in this memorandum and are provided under separate cover. Each appendix is marked PRIVILEGED AND CONFIDENTIAL — ATTORNEY-CLIENT COMMUNICATION — ATTORNEY WORK PRODUCT.

Appendix A: Markman Order — Full Text (34 pages) Filed February 17, 2023 Optiwave Semiconductor Corp. v. Lumos Photonics, Inc., Case No. 5:22-cv-03417-EJD (N.D. Cal.) Hon. Edward J. Torvelis, United States District Judge

Appendix B: Claim Construction Comparison Chart All 11 disputed claim terms across the four patents-in-suit, presented in tabular format showing: (i) OWS's proposed construction, (ii) Lumos's proposed construction, and (iii) the Court's adopted construction, with annotations indicating the prevailing party on each term.

Appendix C: Post-Markman Claim-by-Claim Infringement Viability Analyses Separate memoranda dated February 2023 for each of the four asserted patents (U.S. Patent Nos. 10,234,567; 10,891,234; 11,045,678; and 11,312,890), prepared by the Calderwood & Harkness IP litigation team, analyzing the viability of OWS's infringement theories under the Court's adopted claim constructions, including assessment of literal infringement and doctrine-of-equivalents theories.

Appendix D: Clearpath IP Valuation Services — Original Pre-Litigation Valuation Report Summary Lead Analyst: Jennifer Armitage, CFA, CLP Portfolio Valuation: $215 million (87 issued U.S. patents) Four Asserted Patents Valuation: $42.8 million (19.9% of portfolio value) Valuation Methodology: Income-based approach with comparable license rate analysis

Appendix E: Litigation Financial Summary Total Expenditures to Date: $2,549,568

End of Memorandum PRIVILEGED AND CONFIDENTIAL — ATTORNEY-CLIENT COMMUNICATION — ATTORNEY WORK PRODUCT Calderwood & Harkness LLP	C&H Matter No. 1014-00003 © 2023 Calderwood & Harkness LLP. All rights reserved.
Category	Vendor	Amount
Legal Fees	Calderwood & Harkness LLP	$1,847,312

Litigation

PRIVILEGED AND CONFIDENTIAL — ATTORNEY-CLIENT COMMUNICATION — ATTORNEY WORK PRODUCT This memorandum is protected by the attorney-client privilege and the work product doctrine. It is intended solely for the use of the addressees identified herein. Any dissemination, distribution, or copying of this memorandum by any person other than the intended recipients or their authorized representatives is strictly prohibited. If you have received this memorandum in error, please notify Calderwood & Harkness LLP immediately.
MEMORANDUM
February 23, 2023
FROM: Alan Ngo, Responsible Partner, intellectual Property Group Calderwood & Harkness LLP One Embarcadero Center, 34th Floor San Francisco, CA 94111
TO: Douglas Fairbanks III, Managing Partner Vantage Point Capital Partners Fund IV, LP 2600 Sand Hill Road, Suite 200 Menlo Park, CA 94025
Rebecca Torres, Operating Partner (Semiconductor Sector) Vantage Point Capital Partners Fund IV, LP 2600 Sand Hill Road, Suite 200 Menlo Park, CA 94025
RE: Post-Markman Litigation Value Assessment — Optiwave Semiconductor Corp. v. Lumos Photonics, Inc., Case No. 5:22-cv-03417-EJD (N.D. Cal.)
C&H MATTER NO.: 1014-00003
COPIES: Sandra Ellison, General Counsel, Optiwave Semiconductor Corp. (privileged copy) Marcus Delgado, Billing Partner, Calderwood & Harkness LLP (privileged copy) Omar Siddiqui, Lead Associate, Calderwood & Harkness LLP (privileged copy)
Right-click to update Table of Contents
I. Executive Summary
The purpose of this memorandum is to advise Vantage Point Capital Partners Fund IV, LP ("Vantage Point" or "VPCP"), as the majority shareholder holding approximately 62% of the outstanding equity of Optiwave Semiconductor Corp. ("OWS" or the "Company"), regarding the material adverse impact of the Markman claim construction order (the "Markman Order") issued on February 17, 2023, by the Honorable Edward J. Torvelis of the United States District Court for the Northern District of California, on the value of OWS's patent infringement litigation against Lumos Photonics, Inc. ("Lumos" or "Defendant"). This memorandum is being provided in advance of the OWS Board of Directors meeting scheduled for February 24, 2023, at which the Board will consider next steps, including settlement authorization.
The Markman Order construed all eleven disputed claim terms across the four patents-in-suit: U.S. Patent Nos. 10,234,567 (the "'567 Patent"), 10,891,234 (the "'234 Patent"), 11,045,678 (the "'678 Patent"), and 11,312,890 (the "'890 Patent"). The outcome was overwhelmingly unfavorable to OWS. The Court adopted Defendant's proposed constructions, or constructions substantially aligned with Defendant's proposals, on eight of the eleven disputed claim terms. The Court adopted Plaintiff's proposed constructions on only two terms and issued a modified construction on one additional term that, in substance, remains closer to Defendant's position than to Plaintiff's.
The bottom-line assessment of Calderwood & Harkness's intellectual Property Group is as follows: the Court's narrow constructions render OWS's infringement theories untenable as to three of the four asserted patents (the '567 Patent, the '234 Patent, and the '678 Patent) and significantly weakened as to the fourth (the '890 Patent). The accused Lumos products — the LumosBridge™ 800G Optical Engine and the LumosEdge™ 400ZR+ Pluggable Transceiver — fall outside the scope of the asserted claims as now construed by the Court, with the possible narrow exception of certain claims of the '890 Patent, where only a slim and high-risk doctrine-of-equivalents theory survives, undermined by prosecution history estoppel.
The pre-litigation collective valuation of the four asserted patents at $42.8 million, as determined by Clearpath IP Valuation Services, Inc. in its independent appraisal, is materially impaired. That valuation assumed a reasonable probability of obtaining favorable claim constructions and sustaining infringement theories — an assumption that the Markman Order has now invalidated. The expected litigation recovery, previously estimated at in excess of $75 million based on a reasonable royalty damages theory, has been reduced to near-zero.
Calderwood & Harkness recommends that OWS pursue settlement discussions with Lumos through its litigation counsel, Brannick Howell & Stein LLP. A Board meeting is scheduled for February 24, 2023, to discuss settlement authority and next steps. This memorandum is intended to provide Vantage Point with a comprehensive assessment so that its Board representatives can participate in that discussion on a fully informed basis.
We note that Vantage Point's $74.5 million equity investment in OWS (through the Series C and Series D rounds) is not directly at risk from this development. However, OWS's IP portfolio value — which is a significant driver of the Company's enterprise value and a material factor in any future exit transaction, whether by way of M&A or IPO — is diminished by the Markman Order. The implications for Vantage Point's investment are discussed in detail below.
II. Background
A. The Litigation
Optiwave Semiconductor Corp. filed this patent infringement action on June 3, 2022, in the United States District Court for the Northern District of California, San Jose Division, asserting four U.S. patents against Lumos Photonics, Inc. The case was assigned to the Honorable Edward J. Torvelis and is docketed as Case No. 5:22-cv-03417-EJD.
Lumos Photonics, Inc. is a publicly traded company (Nasdaq: LMPH) headquartered in San Diego, California, that designs and manufactures photonic integrated circuits and optical transceiver modules for data center and telecommunications applications. As of the filing date of this action, Lumos's market capitalization was approximately $1.87 billion. Its largest institutional shareholder is Ridgeline Asset Management, LLC, which held an approximately 9.2% equity stake as of Lumos's most recent proxy filing. Lumos is represented in this litigation by Brannick Howell & Stein LLP, with Victoria Ashworth serving as lead partner.
The accused products are the LumosBridge™ 800G Optical Engine, a co-packaged optics module designed for next-generation data center switch architectures, and the LumosEdge™ 400ZR+ Pluggable Transceiver, a coherent optical transceiver conforming to the OIF 400ZR+ multi-source agreement specification. These are Lumos's two highest-revenue products and are central to the company's growth strategy in the data center interconnect market.
Combined accused product revenue for the LumosBridge™ and LumosEdge™ platforms was approximately $148.6 million for calendar year 2022, as determined from Lumos's annual report on Form 10-K filed with the Securities and Exchange Commission and corroborated by Lumos's discovery responses (specifically, Defendant's Supplemental Responses to Plaintiff's First Set of Interrogatories, served November 14, 2022). The pre-suit damages period, encompassing the first and second quarters of 2022 prior to the filing of the complaint, accounts for approximately $62.3 million of that revenue.
OWS's damages theory, as developed by Dr. Lawrence Kessler of Apex Claim Analytics LLC, is based on a reasonable royalty framework. The estimated royalty rate of 7.5%, derived from an analysis of comparable license agreements in the silicon photonics and optical transceiver industry, was applied to accused product revenue. With the addition of a willfulness enhancement based on OWS's pre-suit notice letters to Lumos (sent January 15, 2022, and March 28, 2022), the total claimed damages exceeded $75 million. This damages theory was developed in conjunction with C&H's litigation team and was the basis for the Board's decision to authorize litigation in April 2022.
The OWS Board of Directors approved a litigation budget of $4.2 million to fund the case through trial, which was projected for the fourth quarter of 2023 under Judge Torvelis's scheduling order. As of the date of this memorandum, total litigation expenditures amount to approximately $2,549,568, comprised of the following:
The remaining estimated cost to litigate through trial is approximately $1.65 million, which would bring total expenditures to approximately $4.2 million — essentially the full approved budget. These estimates are detailed in the litigation financial summary attached as Appendix E.
B. Pre-Litigation Patent Valuation
Prior to filing suit, and in connection with the Board's evaluation of whether to authorize the litigation, OWS engaged Clearpath IP Valuation Services, Inc. to conduct an independent valuation of OWS's U.S. patent portfolio. The engagement was led by Jennifer Armitage, CFA, CLP, Clearpath's Managing Director and lead analyst for semiconductor and photonics IP valuations.
Clearpath valued OWS's total patent portfolio — consisting of 87 issued U.S. patents at the time of the valuation — at $215 million. An additional 14 pending U.S. patent applications were identified but not separately valued, consistent with Clearpath's methodology of valuing only issued patents. The valuation was conducted using an income-based approach that incorporated comparable license rates from arms-length transactions in the silicon photonics, optical transceiver, and semiconductor industries, as well as projected royalty streams from potential licensees based on market sizing and technology adoption forecasts.
The four patents subsequently asserted in this litigation were collectively valued at $42.8 million, representing approximately 19.9% of the total portfolio value. This disproportionate concentration of value in four patents reflected Clearpath's assessment that the asserted patents covered commercially significant and widely practiced technology in the silicon photonics market, including adiabatic waveguide coupling, germanium-on-silicon photodetector architectures, monolithic wavelength-division multiplexing integration, and co-integrated modulator driver circuits.
Critically, Clearpath's valuation assumed a reasonable probability of obtaining favorable claim constructions in litigation and sustaining infringement theories against accused products employing the covered technologies. This assumption was expressly stated in the valuation report and was a material input to the income-based valuation model. As discussed in detail below, this assumption has been invalidated by the Markman Order. The full Clearpath valuation report summary is attached as Appendix D.
C. Vantage Point's Investment Position
Vantage Point Capital Partners Fund IV, LP, a venture capital fund with a 2018 vintage and $2.1 billion in committed capital, is the majority equity holder in OWS. VPCP invested a total of $74.5 million in OWS through two rounds of equity financing: the Series C round (closed August 2019) and the Series D round (closed February 2021). As a result of these investments, VPCP holds approximately 62% of OWS's outstanding equity on a fully diluted basis and controls three of the seven seats on the OWS Board of Directors.
OWS is a fabless semiconductor company specializing in silicon photonics-based coherent optical transceiver chipsets and co-packaged optics engines for data center interconnect applications. The Company's flagship products include the OWS-400ZR coherent optical transceiver chipset, the OWS-800LR long-reach coherent optical engine, and related silicon photonics engines manufactured by Pinnacle Semiconductor Foundry Co., Ltd. on a 45nm silicon-on-insulator (SOI) process. OWS reported fiscal year 2022 revenue of $187.4 million, reflecting strong growth driven by hyperscale data center demand for high-bandwidth optical interconnects.
OWS's intellectual property portfolio is a core component of the Company's enterprise value. The portfolio serves both defensive purposes — providing freedom to operate and cross-licensing leverage against competitors — and offensive purposes, supporting potential licensing revenue and patent assertion against infringers. The IP portfolio has been identified as a key asset in Vantage Point's exit planning, whether through a strategic acquisition by a larger semiconductor or photonics company or through an initial public offering. The Markman Order's impact on the portfolio value is therefore directly relevant to Vantage Point's investment thesis and return expectations.
III. Summary of the Markman Order (February 17, 2023)
On February 17, 2023, the Court issued a 34-page order construing all eleven disputed claim terms across the four patents-in-suit. The full text of the Markman Order is attached as Appendix A. A side-by-side comparison chart showing OWS's proposed constructions, Lumos's proposed constructions, and the Court's adopted constructions for each of the eleven terms is attached as Appendix B.
The Markman hearing was held on January 30, 2023, and lasted approximately six and a half hours. The hearing included live testimony from two technical tutorial witnesses. Dr. Harold Whitfield of Whitfield Technical Consulting Group testified on behalf of OWS, providing a tutorial on silicon photonics device architecture, adiabatic coupling structures, germanium photodetector fabrication, and modulator driver integration. Dr. Raymond Ng, serving as a technical consultant of counsel to Brannick Howell & Stein LLP, testified on behalf of Lumos, presenting a competing tutorial focused on distinguishing monolithic integration from heterogeneous integration techniques, continuous versus step-graded semiconductor buffer layers, and the state of the art in multi-chip packaging for optical transceivers.
The overall scorecard of the Markman Order is as follows:
This is an unusually lopsided result. In C&H's experience litigating patent cases before Judge Torvelis, outcomes in this range — with the defendant prevailing on more than 70% of disputed terms — occur in fewer than 15% of Markman proceedings. The result reflects, in our assessment, a combination of factors: (i) the prosecution histories of the asserted patents, which included multiple amendments and applicant remarks narrowing claim scope to overcome prior art, (ii) effective advocacy by Victoria Ashworth and the Brannick Howell & Stein team, whose intrinsic-evidence analysis was thorough and well-organized, and (iii) certain vulnerabilities in OWS's claim language that, while identified in C&H's pre-suit claim construction risk assessment, were assessed as presenting a moderate rather than high risk of adverse construction. We discuss each of the critical term constructions in turn below, focusing on the four terms with the most significant impact on OWS's infringement theories.
A. '567 Patent — "Adiabatically Coupled" (U.S. Patent No. 10,234,567)
The '567 Patent is directed to adiabatic waveguide coupling structures for silicon photonic integrated circuits. The key disputed term was "adiabatically coupled," which appears in independent Claim 1 and is incorporated by reference into dependent Claims 4, 7, 12, and 15 — the five claims asserted against Lumos.
The parties' competing constructions and the Court's adopted construction are as follows:
OWS's Proposed Construction: "coupled such that optical mode transitions occur without significant power loss."
Lumos's Proposed Construction: "coupled through a gradual, continuous taper that prevents excitation of higher-order modes throughout the entire transition region."
Court's Adopted Construction: "coupled through a gradual, continuous taper designed and configured to prevent excitation of higher-order modes over the entire transition length."
The Court adopted Defendant's proposed construction with only minor, non-substantive modification (replacing "throughout the entire transition region" with "over the entire transition length"). In substance, the Court's construction is identical to Lumos's proposal and imposes the critical limitation that adiabatic coupling, as used in the '567 Patent claims, requires a "gradual, continuous taper."
The critical impact of this construction on OWS's infringement theory is as follows. Lumos's LumosBridge™ 800G Optical Engine employs a segmented, non-continuous taper structure in its waveguide coupling architecture. The Lumos design uses discrete coupling sections — rather than a single continuous taper — to transition optical modes between waveguide layers. Under OWS's proposed construction, which focused on the functional result ("without significant power loss") rather than the structural means, the Lumos segmented taper design would have been captured. Under the Court's construction, which requires a "gradual, continuous taper," the Lumos segmented taper falls squarely outside the claim scope.
The Court's analysis relied heavily on the prosecution history of the '567 Patent. During prosecution, the claims were narrowed by amendment to add the limitation "adiabatically coupled" to overcome a prior art rejection based on U.S. Patent No. 9,456,012, issued September 6, 2016, to Hideo Tanaka (the "Tanaka Patent"). In an irony not lost on either party, Dr. Tanaka is a co-inventor of the Tanaka Patent who subsequently left his prior employer and joined OWS, where he serves as a principal design engineer and contributed to the development of the technology covered by the '567 Patent. The applicant's remarks submitted during prosecution in connection with the amendment adding "adiabatically coupled" distinguished the claimed invention from the Tanaka Patent by emphasizing the gradual, continuous nature of the taper structure. The Court found this prosecution history disclaimer significant, stating that "the applicant's own characterization of 'adiabatic coupling' as requiring a 'gradual, continuous taper' to distinguish the Tanaka reference is entitled to substantial weight and limits the permissible construction of this term." Markman Order at 12.
As a result of this construction, all five asserted claims of the '567 Patent (Claims 1, 4, 7, 12, and 15) cannot be infringed by the accused Lumos products. Infringement is untenable, and no viable theory — whether literal or under the doctrine of equivalents — survives given the prosecution history estoppel arising from the narrowing amendment.
B. '234 Patent — "Continuously Varying Germanium Concentration" (U.S. Patent No. 10,891,234)
The '234 Patent is directed to germanium-on-silicon photodetector structures for use in silicon photonic receivers. The key disputed term was "graded buffer layer having a continuously varying germanium concentration," which appears in independent Claim 1 and is incorporated into dependent Claims 3, 5, 8, and 11 — the five claims asserted against Lumos.
The parties' competing constructions and the Court's adopted construction are as follows:
OWS's Proposed Construction: "a buffer layer in which the germanium concentration changes across the layer thickness."
Lumos's Proposed Construction: "a buffer layer in which the germanium atomic fraction increases monotonically and without step changes from the silicon substrate interface to the absorber layer."
Court's Adopted Construction: The Court adopted Defendant's proposed construction verbatim: "a buffer layer in which the germanium atomic fraction increases monotonically and without step changes from the silicon substrate interface to the absorber layer."
The critical impact of this construction on OWS's infringement theory is as follows. Lumos's photodetector design, as used in both the LumosBridge™ and LumosEdge™ platforms, employs a step-graded silicon-germanium (SiGe) buffer layer with four discrete composition steps. The germanium atomic fractions at each step are 0.25, 0.50, 0.75, and 1.0, progressing from the silicon substrate interface to the germanium absorber layer. This step-graded structure — in which the germanium concentration increases in discrete increments rather than varying continuously — is clearly excluded by the Court's construction requiring a monotonic increase "without step changes."
The Court acknowledged that the '234 Patent specification describes both "continuously graded" and "step-graded" buffer layer embodiments. Indeed, the specification at column 5, lines 22-38, includes a figure and textual description of a step-graded buffer layer as an alternative embodiment. OWS argued that this disclosure supported a broader construction that would encompass both continuous and step-graded structures. The Court disagreed, finding that while the specification described both embodiments, the claim language uses only the term "continuously varying," which the Court held "unambiguously excludes step-graded structures in which the germanium concentration changes in discrete, discontinuous increments." Markman Order at 18. The Court noted that the patentee could have drafted the claims to cover both embodiments — for example, by using the term "graded" without the "continuously varying" modifier — but chose not to do so. The claim language controls and limits the scope to continuous gradation.
As a result of this construction, all five asserted claims of the '234 Patent (Claims 1, 3, 5, 8, and 11) are foreclosed. The Lumos step-graded buffer layer falls outside the claim scope, and no viable infringement theory survives.
C. '678 Patent — "Monolithically Formed" (U.S. Patent No. 11,045,678)
The '678 Patent is directed to integrated wavelength-division multiplexing (WDM) elements for silicon photonic transmitter circuits. The key disputed term was "integrated wavelength-division multiplexing element monolithically formed on a single silicon die," which appears in independent Claim 1 and is incorporated into dependent Claims 2, 6, 9, and 14 — the five claims asserted against Lumos.
The parties' competing constructions and the Court's adopted construction are as follows:
OWS's Proposed Construction: "a WDM component fabricated as part of the same semiconductor fabrication process on a single die."
Lumos's Proposed Construction: "a WDM component formed during front-end-of-line processing within the same silicon substrate, excluding hybrid integration, flip-chip bonding, or any heterogeneous integration technique."
Court's Adopted Construction: "fabricated entirely within the same front-end-of-line and back-end-of-line semiconductor processing sequence on a single silicon substrate without heterogeneous bonding or attachment of separately fabricated optical components."
The Court largely adopted Defendant's proposed construction, though it expanded the scope slightly to include back-end-of-line processing (which Lumos's proposal had arguably excluded) while retaining the critical exclusion of heterogeneous integration techniques. The net result is a construction that requires fully monolithic fabrication — the WDM element must be fabricated entirely within the same semiconductor processing sequence on a single silicon substrate, without the bonding or attachment of separately fabricated components.
The critical impact on OWS's infringement theory is severe. Lumos's 800G optical engine platform utilizes micro-transfer-printed III-V gain elements (indium phosphide-based semiconductor optical amplifiers) that are bonded onto the silicon photonic integrated circuit (PIC) die. This micro-transfer printing process is a form of heterogeneous integration in which separately fabricated III-V semiconductor components are picked and placed onto the silicon die — a technique that falls squarely outside the Court's construction requiring monolithic fabrication "without heterogeneous bonding or attachment of separately fabricated optical components."
The prosecution history of the '678 Patent was particularly damaging. The term "monolithically formed" was added by amendment during prosecution to overcome a prior art rejection based on references describing hybrid integration approaches. In the applicant's remarks accompanying the amendment, OWS's prosecution counsel stated: "The present invention is distinguished from heterogeneous integration approaches in that the WDM element is monolithically formed — i.e., fabricated entirely within the same processing sequence on a single silicon substrate, without the need for bonding or attaching separately fabricated optical components." The Court relied heavily on this prosecution history disclaimer, characterizing it as "an unambiguous disavowal of heterogeneous integration that confines the claim scope to monolithic fabrication." Markman Order at 24.
As a result, all five asserted claims of the '678 Patent (Claims 1, 2, 6, 9, and 14) are foreclosed. The Lumos micro-transfer-printed III-V gain elements are excluded by the "monolithically formed" construction.
D. '890 Patent — "Co-Integrated" (U.S. Patent No. 11,312,890)
The '890 Patent is directed to pre-emphasis equalization driver circuits for silicon photonic modulators. The key disputed term was "pre-emphasis equalization stage electrically co-integrated with the modulator on a common substrate," which appears in independent Claim 1 and is incorporated into dependent Claims 5, 8, and 13 — the four claims asserted against Lumos.
The parties' competing constructions and the Court's adopted construction are as follows:
OWS's Proposed Construction: "an equalization circuit located on the same substrate as the modulator."
Lumos's Proposed Construction: "an equalization circuit fabricated in the same semiconductor process as the modulator, sharing the same doping profiles and process layers, and electrically connected without bond wires, interposers, or package-level routing."
Court's Adopted Construction: The Court adopted Defendant's proposed construction in full: "an equalization circuit fabricated in the same semiconductor process as the modulator, sharing the same doping profiles and process layers, and electrically connected without bond wires, interposers, or package-level routing."
The impact of this construction on OWS's infringement theory is significant. Lumos's modulator driver architecture uses a separate CMOS driver die that is flip-chip bonded to the silicon photonic modulator die via copper pillar micro-bumps. The driver die and the modulator die are fabricated in different semiconductor processes (the driver in a 16nm FinFET CMOS process, the modulator in a 45nm SOI silicon photonics process), and they are electrically connected through the copper pillar micro-bumps — which constitute "bond" connections excluded by the Court's construction. The Lumos architecture is therefore outside the literal scope of the claims as construed.
Unlike the other three patents, however, the '890 Patent presents a theoretically possible — though weak — doctrine-of-equivalents argument. One could argue that Lumos's flip-chip bonded driver performs substantially the same function (pre-emphasis equalization), in substantially the same way (electrical signal conditioning applied to the modulator), to achieve substantially the same result (improved modulator performance) as a co-integrated driver. However, this argument is significantly undermined by prosecution history estoppel. The term "co-integrated" was added during prosecution specifically to distinguish the claimed invention from prior art describing separately fabricated and bonded driver circuits. The prosecution history therefore creates a strong estoppel argument that precludes extending the claims under the doctrine of equivalents to encompass the very bonded-driver configuration that the amendment was designed to exclude.
Additionally, the '890 Patent faces a non-trivial invalidity risk. During claim construction briefing, Lumos identified a prior art publication — Iyer & Patel, "Co-Design of Modulator Drivers and Silicon Photonic Mach-Zehnder Structures," IEEE Transactions on Circuits and Systems, Vol. 65, No. 8, pp. 2701–2713 (2018) — that describes co-integrated driver circuits with pre-emphasis equalization on a common silicon substrate with a Mach-Zehnder modulator. While this reference was cited during prosecution and distinguished on other grounds, it remains relevant to Lumos's anticipated Section 103 obviousness defense, particularly if the claims are construed broadly enough to reach Lumos's flip-chip bonded architecture.
In sum, the asserted claims of the '890 Patent (Claims 1, 5, 8, and 13) are significantly weakened though not entirely foreclosed. A slim doctrine-of-equivalents theory survives, but it is high-risk and would face both prosecution history estoppel and potential invalidity challenges at summary judgment and trial.
IV. Impact on Litigation Value
A. Infringement Viability Assessment
Based on the Markman Order, Calderwood & Harkness has conducted a comprehensive reassessment of the viability of OWS's infringement theories against each of the four asserted patents. The detailed claim-by-claim infringement viability analyses are attached as Appendix C. The summary assessment for each patent is as follows:
'567 Patent (U.S. Patent No. 10,234,567) — Infringement Untenable. The Court's construction of "adiabatically coupled" as requiring a "gradual, continuous taper" excludes the Lumos LumosBridge™ segmented (non-continuous) taper design. All five asserted claims (Claims 1, 4, 7, 12, and 15) depend on this term. Prosecution history estoppel arising from the narrowing amendment to overcome the Tanaka prior art precludes any viable doctrine-of-equivalents theory. This patent is effectively out of the case.
'234 Patent (U.S. Patent No. 10,891,234) — Infringement Untenable. The Court's construction of "continuously varying germanium concentration" as requiring a monotonic increase "without step changes" excludes the Lumos step-graded SiGe buffer layer with four discrete composition steps (Ge fractions of 0.25, 0.50, 0.75, and 1.0). All five asserted claims (Claims 1, 3, 5, 8, and 11) are foreclosed. No viable alternative infringement theory exists.
'678 Patent (U.S. Patent No. 11,045,678) — Infringement Untenable. The Court's construction of "monolithically formed" as excluding "heterogeneous bonding or attachment of separately fabricated optical components" excludes the Lumos micro-transfer-printed III-V gain elements bonded to the silicon PIC. All five asserted claims (Claims 1, 2, 6, 9, and 14) are foreclosed. The prosecution history disclaimer — in which the applicant expressly distinguished the invention from heterogeneous integration approaches — eliminates any doctrine-of-equivalents theory.
'890 Patent (U.S. Patent No. 11,312,890) — Infringement Significantly Weakened. The Court's construction of "co-integrated" as requiring fabrication "in the same semiconductor process" and connection "without bond wires, interposers, or package-level routing" excludes the Lumos flip-chip bonded CMOS driver die. The four asserted claims (Claims 1, 5, 8, and 13) survive only under a slim doctrine-of-equivalents theory, which is substantially undermined by prosecution history estoppel and faces additional invalidity risk from the Iyer & Patel prior art reference.
Net Assessment: Three of the four asserted patents are effectively out of the case. The fourth patent offers only a marginal, high-risk infringement theory with a low probability of surviving summary judgment. The litigation posture has shifted from one in which OWS held a credible multi-patent infringement case to one in which OWS's claims are, for practical purposes, non-viable.
B. Damages Implications
The adverse claim constructions have a cascading effect on OWS's damages case. The previously estimated damages of in excess of $75 million were predicated on a reasonable royalty theory applying a 7.5% royalty rate to the full $148.6 million in combined accused product revenue for the LumosBridge™ and LumosEdge™ platforms, with an additional willfulness enhancement. This damages framework assumed that all four asserted patents would be in play and that the accused products, in their entirety, practiced the claimed inventions.
With only the '890 Patent potentially remaining in the case — and weakly — the damages analysis must be fundamentally reconsidered. The '890 Patent relates specifically to the pre-emphasis equalization driver circuit architecture. Under accepted apportionment principles, the royalty base for a single component-level patent covering only the driver circuit would need to be limited to the portion of accused product revenue attributable to the driver circuit architecture, rather than the full product revenue. The driver circuit represents a small fraction of the overall value of the LumosBridge™ and LumosEdge™ platforms, which derive their commercial value primarily from the complete photonic integrated circuit — including the waveguide coupling, photodetector, WDM multiplexer, and modulator elements (the very components addressed by the three foreclosed patents).
Dr. Lawrence Kessler's preliminary damages framework, developed on behalf of OWS by Apex Claim Analytics LLC, is effectively mooted by the Markman Order. The framework was designed as a multi-patent damages model apportioning royalty value across all four asserted patents. With three patents eliminated, the model cannot simply be scaled down — it must be rebuilt from the ground up, an exercise that would require additional expert fees and would yield a dramatically reduced damages figure.
Even under the most optimistic assumptions — if the '890 Patent infringement theory survived summary judgment and the case proceeded to trial on that single patent — the expected recovery would be in the low single-digit millions at most. A royalty rate of 2-3% (reflecting the narrower technology contribution of the driver circuit alone) applied to a reduced royalty base (the driver-attributable portion of accused product revenue, estimated at 8-12% of total product revenue, or approximately $12-18 million) would yield a pre-enhancement royalty of approximately $240,000 to $540,000. Even with a willfulness enhancement (which would be difficult to sustain given the post-Markman posture), the total recovery would be unlikely to exceed $1.5-2.0 million — well below the remaining litigation cost to reach trial.
C. Revised Expected Value Calculation
The litigation expected value calculation has changed dramatically as a result of the Markman Order. The following table summarizes the pre-Markman and post-Markman expected value assessments:
The pre-Markman expected value of the litigation was estimated at $35–50 million on a probability-weighted basis. This estimate incorporated a 45-65% probability of a favorable overall outcome (accounting for claim construction risk, summary judgment risk, and trial risk), multiplied by expected damages in the $55-80 million range (reflecting the full multi-patent damages theory with some discount for litigation uncertainty). This expected value supported the Board's decision to authorize the filing of the lawsuit and the allocation of a $4.2 million litigation budget.
The post-Markman expected value is estimated at less than $2 million. This reflects a probability of less than 5% that OWS will achieve a favorable outcome on the '890 Patent alone (accounting for the slim doctrine-of-equivalents theory, prosecution history estoppel, invalidity risk, and summary judgment risk), multiplied by a reduced damages figure of $1.5-2.0 million. Against the remaining estimated litigation cost of approximately $1.65 million to reach trial, the net expected value of continued litigation is negative.
In plain terms, OWS would be expected to spend more on continued litigation than it would expect to recover, on a probability-weighted basis. The rational economic decision is to discontinue affirmative pursuit of the case and seek to resolve the matter through settlement.
V. Impact on Patent Portfolio Valuation
A. The Four Asserted Patents
The most immediate valuation impact of the Markman Order falls on the four asserted patents. Clearpath IP Valuation Services' pre-litigation valuation of these four patents at a collective $42.8 million must be materially revised downward.
The Court's narrow constructions do not merely impair OWS's ability to assert these patents against Lumos — they reduce the effective scope of each patent for all purposes, including licensing to third parties, assertion against other potential infringers, and use as defensive assets in cross-licensing negotiations. The key claim terms that were narrowly construed — "adiabatically coupled," "continuously varying germanium concentration," "monolithically formed," and "co-integrated" — are the same terms that define the breadth of each patent's coverage in the marketplace. A patent that covers only continuous tapers and not segmented tapers, only continuous grading and not step grading, only monolithic fabrication and not heterogeneous integration, and only same-process co-integration and not multi-chip bonded architectures, is a patent that covers a much smaller universe of potentially infringing products than previously assumed.
While the Markman Order is technically binding only in this case and not in other jurisdictions, any future assertion of these four patents — whether in a new infringement action in another district court, in an International Trade Commission investigation, or in a licensing negotiation — will be significantly influenced by the existing constructions. Accused infringers and potential licensees will point to the Markman Order as persuasive authority for a narrow reading of the claims. Although a different court could, in theory, adopt a different construction, the practical reality is that the existing constructions will anchor any future claim construction analysis and make it extremely difficult for OWS to obtain the broader constructions it originally sought.
The estimated revised value of the four asserted patents is significantly impaired, potentially to $5-10 million or less. The precise value will depend on whether any third-party products or technologies fall within the narrow constructions adopted by the Court, and on the remaining commercial life of the patents (the earliest expiration date among the four patents is 2037). C&H recommends that Clearpath be engaged to conduct a formal revaluation of these four patents in light of the Markman Order.
B. Broader Portfolio Implications
The impact of the Markman Order extends beyond the four asserted patents to OWS's broader patent portfolio. OWS holds 87 issued U.S. patents and 14 pending U.S. patent applications. The portfolio is concentrated in three primary technology areas: (i) waveguide coupling structures (including adiabatic and evanescent coupling), (ii) germanium-on-silicon photodetector architectures (including buffer layer designs and epitaxial growth techniques), and (iii) modulator driver and transceiver integration architectures (including co-packaged optics designs). These are the same technology areas directly impacted by the Markman Order.
While the Markman Order's claim constructions technically apply only to the four asserted patents, they establish judicial interpretive precedent for related claim language that appears throughout OWS's portfolio. Many of OWS's unasserted patents use similar or identical terminology — including "adiabatic," "continuously graded," "monolithic," and "co-integrated" — in their claims. A potential licensee or adverse party reviewing the portfolio in light of the Markman Order would reasonably conclude that these terms, if litigated, would receive similarly narrow constructions, thereby reducing the effective scope of the broader portfolio.
Based on a preliminary review of the claim language in OWS's portfolio, C&H estimates that the Markman Order may require a downward adjustment to Clearpath's portfolio-level valuation of $215 million in the range of 10-20%, or approximately $21.5-43.0 million. The precise magnitude of the adjustment will depend on a patent-by-patent analysis of how many additional patents share similarly vulnerable claim language and how dependent their value is on the breadth of the construed terms. C&H recommends that Clearpath IP Valuation Services be re-engaged to conduct an updated portfolio valuation incorporating the Markman Order and its implications for related patents.
Additionally, we note that OWS's IP portfolio serves as partial collateral for the Company's $40 million revolving credit facility with First Pacific Commerce Bank, N.A. ("FPCB"). The credit agreement includes customary representations regarding the value of collateral and may contain financial covenants tied to intangible asset values. Any material write-down of IP portfolio value could trigger covenant compliance discussions with FPCB. Sandra Ellison and C&H will coordinate on reviewing the specific covenant provisions and determining the appropriate disclosure to FPCB, as discussed further in Section VII.C below.
C. IP Monetization Strategy
The Markman Order has broader implications for OWS's IP monetization strategy. The Company's ability to use its patent portfolio as a licensing revenue stream — whether through affirmative licensing programs, patent assertion against infringers, or defensive cross-licensing arrangements with competitors — is diminished by the narrow claim constructions.
The constructions are particularly damaging because they narrow the patents' coverage in precisely the areas where the industry is trending. The silicon photonics industry has increasingly moved toward heterogeneous integration (using micro-transfer printing, wafer bonding, and other techniques to integrate III-V materials onto silicon photonic circuits), step-graded buffer layers (which are simpler to fabricate and more widely used than continuously graded buffers), segmented taper designs (which offer design flexibility advantages over continuous tapers), and multi-chip packaging with flip-chip bonding (which enables the use of advanced CMOS nodes for driver circuits while maintaining silicon photonics for the optical layer). The Markman Order's narrow constructions effectively exclude these industry-standard approaches from the scope of OWS's key patents, limiting the patents to a shrinking segment of the market that uses fully monolithic, continuously graded, and continuously tapered designs.
In the context of cross-licensing negotiations with competitors, OWS's leverage is reduced. The Company previously maintained a strong bargaining position based in part on the breadth of its patent portfolio and the credible threat of infringement assertions. The Markman Order weakens that threat and reduces the value that OWS can extract in cross-licensing arrangements.
Looking forward, OWS's patent prosecution strategy should be revisited. Pending patent applications should be drafted — or amended, if still possible within prosecution timelines — with claim language that avoids the vulnerabilities exposed in this Markman proceeding. In particular, claims should be drafted to explicitly cover both continuous and step-graded structures, both monolithic and heterogeneous integration, and both co-integrated and multi-chip bonded driver architectures, to the extent supported by the specification disclosures. Ted Marchetti, OWS's VP of IP, and OWS's patent prosecution counsel should be engaged to conduct this review promptly.
VI. Impact on OWS Enterprise Value and Exit Considerations
For purposes of Vantage Point's investment thesis and exit planning, the Markman Order's impact must be assessed in the context of OWS's overall enterprise value.
OWS's enterprise value is driven by several factors, including: (i) the Company's revenue-generating product business (the OWS-400ZR and OWS-800LR chipsets and silicon photonics engines), (ii) the Company's technology and engineering team, (iii) the Company's customer relationships with hyperscale data center operators and network equipment manufacturers, and (iv) the Company's intellectual property portfolio. The IP portfolio has historically been a significant component of enterprise value, serving both as a defensive moat protecting OWS's market position and as an independent source of potential licensing revenue.
The Markman Order's narrowing of key patent claims reduces both the defensive and offensive value of the IP portfolio. Defensively, the narrow constructions reduce OWS's ability to prevent competitors from entering the market with products that practice the broad technology concepts underlying OWS's patents — competitors can now employ segmented tapers, step-graded buffers, heterogeneous integration, and multi-chip bonded drivers without concern about infringing the asserted patents (and likely without concern about infringing other OWS patents that use similar claim language). Offensively, the narrow constructions reduce the licensing and assertion value of the portfolio, as discussed in Section V above.
In an M&A context, a potential acquirer's intellectual property due diligence would uncover the Markman Order. Any sophisticated acquirer — particularly a strategic acquirer in the semiconductor or photonics space — would review the claim constructions, assess their impact on the breadth and enforceability of the portfolio, and discount the IP component of the acquisition price accordingly. The magnitude of this discount would depend on the acquirer's specific interest in the patents (a company interested in the patents primarily for defensive purposes might apply a smaller discount than one interested in licensing revenue potential), but the Markman Order would unquestionably be a negative factor in acquisition negotiations.
In an IPO context, the diminished patent portfolio value would need to be disclosed in the Company's risk factors. A registration statement that failed to disclose the Markman Order and its impact on the portfolio would expose OWS and its officers and directors to securities liability. The disclosure itself — that a federal court narrowly construed key patent claims, rendering infringement theories untenable as to three of four asserted patents — would be a negative signal to public market investors evaluating OWS's competitive position and growth prospects.
It is important to note, however, that the Markman Order does not affect OWS's core revenue-generating business. OWS's product roadmap, customer relationships, manufacturing arrangements with Pinnacle Semiconductor Foundry, and market position in the coherent optical transceiver and co-packaged optics market remain intact. The Company reported strong fiscal year 2022 revenue of $187.4 million, and the demand for OWS's products from hyperscale data center customers continues to grow. The Markman Order affects only OWS's IP assertion capabilities — not its ability to design, manufacture, and sell its products. The Company's freedom to operate is not at issue, and OWS faces no counterclaim or declaratory judgment risk from Lumos that would threaten its product lines.
Accordingly, while the Markman Order represents a material impairment to one component of OWS's enterprise value, it does not fundamentally alter the Company's core business proposition. Vantage Point's investment thesis, to the extent it was predicated on OWS's product revenue growth and market position (rather than on IP monetization or litigation recovery), remains substantially intact.
VII. Recommended Course of Action
A. Settlement
Calderwood & Harkness recommends that OWS initiate settlement discussions with Lumos Photonics, Inc. through Lumos's litigation counsel, Brannick Howell & Stein LLP. The objective of these discussions should be to resolve the litigation on the most favorable terms available given OWS's significantly weakened post-Markman posture, while minimizing further expenditure of legal fees and management time.
Given the post-Markman posture, OWS's litigation leverage is minimal. Lumos is likely aware that its claim construction victories have effectively gutted OWS's case, and Victoria Ashworth and the BHS team will negotiate accordingly. Realistic settlement outcomes, in C&H's assessment, range from:
(a) A mutual cross-license agreement with nominal or de minimis royalty payments, providing both parties with freedom to operate under each other's patent portfolios going forward;
(b) A mutual walk-away with full mutual releases and covenant not to sue, with no monetary payment in either direction; or
(c) In a less favorable scenario, a settlement in which OWS agrees to dismiss the case with prejudice and pays a portion of Lumos's attorneys' fees in exchange for mutual releases (though C&H would resist this outcome).
Continuing the litigation through trial would cost an estimated additional $1.65 million — including expert deposition costs, summary judgment briefing, pretrial preparation, and trial itself — with a near-zero expected return. This expenditure would be economically irrational in light of the post-Markman expected value analysis set forth in Section IV.C above.
A Board meeting is scheduled for February 24, 2023, at which the Board will be asked to authorize settlement discussions and establish settlement parameters. This memorandum is intended to inform Vantage Point's position in advance of that discussion so that Vantage Point's three Board representatives can participate on a fully informed basis. C&H recommends that Vantage Point support settlement authorization and concur in a resolution that minimizes further expenditure while preserving OWS's relationship with the patent system and its ability to prosecute and enforce its broader portfolio going forward.
B. Portfolio Remediation
Independent of the settlement decision, C&H recommends the following portfolio remediation steps:
Updated Portfolio Valuation. Engage Clearpath IP Valuation Services, Inc. to conduct an updated valuation of OWS's full patent portfolio, reflecting the Markman Order and its implications for the four asserted patents as well as related patents in the portfolio that use similar claim language. This updated valuation will be necessary for financial reporting purposes, for assessing compliance with credit facility covenants, and for informing Vantage Point's enterprise value assessment and exit planning.
Pending Application Review. Work with Ted Marchetti (OWS VP of IP) and OWS's patent prosecution counsel to conduct a comprehensive review of all 14 pending U.S. patent applications. The objective of this review is to identify applications where claims can be amended — or continuation applications filed — with claim language drafted to cover broader embodiments of the claimed technology. Specifically, new or amended claims should be drafted to encompass:
(i) Segmented and discontinuous taper structures, in addition to continuous tapers;
(ii) Step-graded buffer layers, in addition to continuously graded buffers;
(iii) Heterogeneous integration techniques, including micro-transfer printing, wafer bonding, and flip-chip bonding, in addition to monolithic fabrication; and
(iv) Multi-chip bonded driver architectures, in addition to co-integrated same-process drivers.
This prosecution strategy, if executed promptly, could result in new patent claims that cover a broader range of industry-standard designs and partially offset the value impairment caused by the Markman Order. However, this is a medium-to-long-term effort, and new claims would need to be supported by adequate specification disclosure in the parent applications.
Reissue and Reexamination. C&H will evaluate whether any of the four asserted patents may be candidates for reissue under 35 U.S.C. § 251 or ex parte reexamination under 35 U.S.C. § 302, with the objective of obtaining broader claims that might survive the narrow constructions. Reissue is available within two years of patent issuance (or at any time to narrow claims), and the availability of reissue for the asserted patents will depend on whether the statutory requirements are met and whether broader claims can be obtained without running afoul of the prior art. This is a long-term effort with uncertain outcome, and C&H does not recommend relying on it as a primary remediation strategy.
C. Lender Communication
OWS's $40 million revolving credit facility with First Pacific Commerce Bank, N.A. includes OWS's IP portfolio as partial collateral. The Markman Order may constitute a material development that requires disclosure to FPCB under the credit agreement's reporting covenants. Sandra Ellison and C&H will coordinate on the following steps:
(a) Review the specific covenant provisions of the FPCB credit agreement to determine whether the Markman Order triggers any reporting obligations or covenant compliance issues;
(b) Assess whether the reduced IP portfolio value affects compliance with any financial covenants tied to intangible asset values or collateral coverage ratios; and
(c) Prepare appropriate disclosure communications to FPCB, in consultation with OWS's finance team and Vantage Point, that accurately describe the Markman outcome without unnecessarily alarming the lender or jeopardizing the credit relationship.
This communication should be handled carefully. The objective is to maintain transparency with the lender while avoiding any overstatement of the impact that could lead FPCB to declare a default, accelerate the facility, or impose onerous additional conditions.
D. Lessons for Future IP Strategy
The Markman outcome provides important lessons for OWS's future IP strategy, both in prosecution and in litigation:
Claim Construction Risk Assessment. Pre-suit claim construction risk assessment should incorporate more rigorous Markman simulation, including adversarial construction of key claim terms. C&H's pre-suit assessment identified the construed terms as presenting moderate risk, but a more rigorous analysis — including engagement of an outside claim construction expert to develop and argue adversarial constructions — might have more accurately assessed the risk as high and potentially altered the Board's decision to authorize litigation. Going forward, C&H recommends that any patent assertion decision be preceded by a formal adversarial claim construction exercise in which C&H attorneys role-play both sides and present competing constructions to a neutral evaluator.
Patent Prosecution Discipline. Patent prosecution should avoid amendments that create prosecution history estoppel narrowing claims beyond the intended scope. The Markman Order was heavily influenced by prosecution history disclaimers made during the prosecution of the '567 Patent (where "adiabatically coupled" was added to overcome the Tanaka prior art, with applicant remarks emphasizing continuous tapers) and the '678 Patent (where "monolithically formed" was added to overcome hybrid integration references, with applicant remarks expressly distinguishing heterogeneous integration). In both cases, the amendments and accompanying remarks were made to overcome specific prior art rejections, but they had the unintended consequence of narrowing the claims far more than may have been necessary. OWS's prosecution counsel should adopt a more disciplined approach to claim amendments, ensuring that narrowing language is no broader than necessary to overcome the specific prior art at issue and that applicant remarks are carefully drafted to avoid sweeping disclaimers.
VIII. Conclusion
The Markman Order issued on February 17, 2023, in Optiwave Semiconductor Corp. v. Lumos Photonics, Inc., Case No. 5:22-cv-03417-EJD, represents a materially adverse development for OWS. The Court's adoption of narrow, Defendant-aligned claim constructions on eight of eleven disputed terms substantially eliminates OWS's ability to prove infringement and recover damages from Lumos Photonics.
Three of the four asserted patents — the '567 Patent, the '234 Patent, and the '678 Patent — are effectively out of the case. The fourth, the '890 Patent, survives only under a slim doctrine-of-equivalents theory that is undermined by prosecution history estoppel and faces additional invalidity risk. The expected litigation recovery has been reduced from over $75 million to near-zero, and the net expected value of continued litigation is negative.
The total litigation spend to date of $2,549,568 — comprising $1,847,312 in C&H legal fees, $289,456 in litigation costs, and $412,800 in expert fees — will not be recovered. This is a sunk cost that must be accounted for in OWS's financial reporting.
The impairment extends beyond this lawsuit. The Markman Order diminishes the value of the four asserted patents for all purposes (licensing, assertion, cross-licensing), and the narrow constructions have broader implications for OWS's patent portfolio, which is concentrated in the same technology areas and uses similar claim language. The portfolio-level valuation may require a downward adjustment of 10-20%, with potential implications for the FPCB credit facility and for Vantage Point's exit planning.
Calderwood & Harkness recommends that Vantage Point support settlement authorization at the February 24, 2023 Board meeting and concur in a resolution that minimizes further expenditure. The litigation has reached a point where continued pursuit cannot be justified on economic grounds, and the Company's resources are better directed toward portfolio remediation and continued execution of its product business.
C&H remains available to discuss this memorandum with Vantage Point's deal team at any time prior to the Board meeting. Alan Ngo can be reached at the San Francisco office at (415) 555-0147 or by email at a.ngo@calderwoodharkness.com. We would welcome the opportunity to walk through the Markman Order and its implications in a call or in-person meeting at Vantage Point's convenience.
Respectfully submitted,
CALDERWOOD & HARKNESS LLP
By: ________
Alan Ngo Responsible Partner, intellectual Property Group One Embarcadero Center, 34th Floor San Francisco, CA 94111 (415) 555-0147 a.ngo@calderwoodharkness.com
Appendices
The following appendices are referenced in this memorandum and are provided under separate cover. Each appendix is marked PRIVILEGED AND CONFIDENTIAL — ATTORNEY-CLIENT COMMUNICATION — ATTORNEY WORK PRODUCT.
Appendix A: Markman Order — Full Text (34 pages) Filed February 17, 2023 Optiwave Semiconductor Corp. v. Lumos Photonics, Inc., Case No. 5:22-cv-03417-EJD (N.D. Cal.) Hon. Edward J. Torvelis, United States District Judge
Appendix B: Claim Construction Comparison Chart All 11 disputed claim terms across the four patents-in-suit, presented in tabular format showing: (i) OWS's proposed construction, (ii) Lumos's proposed construction, and (iii) the Court's adopted construction, with annotations indicating the prevailing party on each term.
Appendix C: Post-Markman Claim-by-Claim Infringement Viability Analyses Separate memoranda dated February 2023 for each of the four asserted patents (U.S. Patent Nos. 10,234,567; 10,891,234; 11,045,678; and 11,312,890), prepared by the Calderwood & Harkness IP litigation team, analyzing the viability of OWS's infringement theories under the Court's adopted claim constructions, including assessment of literal infringement and doctrine-of-equivalents theories.
Appendix D: Clearpath IP Valuation Services — Original Pre-Litigation Valuation Report Summary Lead Analyst: Jennifer Armitage, CFA, CLP Portfolio Valuation: $215 million (87 issued U.S. patents) Four Asserted Patents Valuation: $42.8 million (19.9% of portfolio value) Valuation Methodology: Income-based approach with comparable license rate analysis
Appendix E: Litigation Financial Summary Total Expenditures to Date: $2,549,568
End of Memorandum PRIVILEGED AND CONFIDENTIAL — ATTORNEY-CLIENT COMMUNICATION — ATTORNEY WORK PRODUCT Calderwood & Harkness LLP | C&H Matter No. 1014-00003 © 2023 Calderwood & Harkness LLP. All rights reserved.
Category | Vendor | Amount
Legal Fees | Calderwood & Harkness LLP | $1,847,312
Litigation

MEMORANDUM

C&H MATTER NO.: 1014-00003

CALDERWOOD & HARKNESS LLP

Record

Parties

Dates

Amounts